4.5 Article

The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations

Journal

HUMAN MUTATION
Volume 36, Issue 4, Pages 395-402

Publisher

WILEY
DOI: 10.1002/humu.22758

Keywords

DMD; Duchenne muscular dystrophy; TREAT-NMD; rare disease registries

Funding

  1. TREAT-NMD [FP6LSHM-CT-2006-036825, 20123307 UNEW_FY2013, AFM 16104]
  2. European Union [305444, 305121]
  3. MRC [MR/K000608/1] Funding Source: UKRI
  4. Medical Research Council [MR/K000608/1] Funding Source: researchfish
  5. National Institute for Health Research [NF-SI-0512-10036] Funding Source: researchfish
  6. Grants-in-Aid for Scientific Research [24591284] Funding Source: KAKEN

Ask authors/readers for more resources

Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available